Pfizer was established more than 150 years ago and is a world-leading biopharmaceutical company with an established heritage in drug discovery and development. Pfizer strives to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with their responsibility as one of the world's premier innovative biopharmaceutical companies, theycollaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Pfizer has recently established a new Machine Learning Research department, which will bring its strong scientific expertise to this project. The new group consists of highly respected scientists in the field of machine learning whose scientific career includes publications in the most prestigious forums of machine learning, such as ICLR, ICML and NeurIPS. The group has an excellent track record in learning on graphs, e.g., for equivariant message passing for the prediction of tensorial properties and molecular spectra or for learning unsupervised permutation-invariant graph-level representations. Fellows will learn how to apply machine learning techniques in the scope of drug discovery projects and how to develop molecular descriptors that can be used in the context of optimization of chemical reactions.